Your session is about to expire
← Back to Search
Light Therapy
Excimer Light for Alopecia Areata
Phase 2
Waitlist Available
Led By Harvey Lui, MD FRCPC
Research Sponsored by University of British Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Subject has a patch of at least 12 cm2 on the scalp with no evidence of hair regrowth
Age > 18 years
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 6, 12, and 16 weeks from baseline
Awards & highlights
Study Summary
This trial will assess whether UVB excimer light is an effective and safe treatment for alopecia areata, a chronic autoimmune inflammatory disease that causes nonscarring hair loss.
Who is the study for?
This trial is for adults over 18 with Alopecia Areata who have a bald patch of at least 12 cm2 without hair regrowth. It's not for those with a history of skin cancer, pregnant or breastfeeding individuals, anyone treated for alopecia in the last month, participants in recent drug/device trials, or people with total hair loss, photosensitivity disorders.Check my eligibility
What is being tested?
The study tests UVB excimer light as a treatment for Alopecia Areata by comparing its effects on two different areas of the same person's scalp. This method aims to determine how effective and safe this light therapy is in promoting hair growth.See study design
What are the potential side effects?
While specific side effects are not listed here, UVB excimer light treatments may generally cause skin redness, itching or burning sensations at the site of application. Long-term safety regarding skin changes or potential cancer risk will be monitored.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have a bald spot of at least 12 cm2 on my scalp with no hair regrowth.
Select...
I am older than 18 years.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ at 6, 12, and 16 weeks from baseline
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 6, 12, and 16 weeks from baseline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in the percentage of hair regrowth for each half. We will consider the treamtment successful if there was ≥50% hair regrowth from baseline.
Secondary outcome measures
Assessment of side effects in each half
Change in hair count and caliber in each half
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: UVB excimer lightExperimental Treatment1 Intervention
Patches of alopecia will be treated twice weekly with UVB excimer light. Only one half of a single alopecia areata patch will be treated. In order to treat the same half during each visit, a transparent sheet will be marked, using a marking pen, to delineate the borders of the treatment area with a central dividing line. The other half will be covered and used as a control. Treatments will be given randomly (by sealed envelope randomization method) into one of the two halves in different patients but will be given into the same half in each patient in all treatment sessions. Only one investigator will know the intervention each half has received. A total of 23 treatments will be given over 12 weeks.
Group II: No treatment (covered)Active Control1 Intervention
Find a Location
Who is running the clinical trial?
University of British ColumbiaLead Sponsor
1,415 Previous Clinical Trials
2,466,998 Total Patients Enrolled
3 Trials studying Alopecia Areata
65 Patients Enrolled for Alopecia Areata
Harvey Lui, MD FRCPCPrincipal InvestigatorUniversity of British Columbia
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have been treated for hair loss in the last 4 weeks.You have complete hair loss on your scalp or entire body.I have had skin cancer in the past.I have a bald spot of at least 12 cm2 on my scalp with no hair regrowth.I am older than 18 years.I am willing and able to follow the study's requirements.I have a condition that makes my skin highly sensitive to sunlight.
Research Study Groups:
This trial has the following groups:- Group 1: UVB excimer light
- Group 2: No treatment (covered)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is there an opportunity to join this research endeavor at present?
"According to clinicaltrials.gov, this trial is no longer recruiting participants as the most recent data update was on June 30th 2015. Nevertheless, there are 85 other medical studies that are actively sourcing candidates right now."
Answered by AI
Has the FDA approved UVB excimer light for patient use?
"Our assessment was that UVB excimer light is a safe therapy, with its safety score being a 2. This evaluation takes into consideration the fact that this experiment is in Phase 2, and thus there are data points to support its security but no evidence of clinical efficacy yet."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger